Loading patent…
AssigneesInstitute of Nuclear Energy Research Rocaec, Tty Biopharm Company Limited
InventorsTe-Wei Lee, Chun-Ying Huang, Ming-Shiuan Wu, Te-Jung Chen, Kwo-Ping Chang, Shiang-Rong Chang, Shyh-Yi Chyi, Chih-Hsien Chang, Yin-Mao Hsu, Kuo-Hsien Fan, Wei-Chuan Hsu, Ying-Kai Fu, Charng-Feng Kao
Estimating the term…
This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, As2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i). This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.
A method for treating a subject having a tumor or cancer, comprising the step of administering to the subject a radioactive arsenic-containing compound prepared by a process comprising the steps of:
A pharmaceutical composition for treating a tumor or cancer, comprising:
Dependencies are inferred from the claim text.